

Product Data Sheet

Product Name: Cedazuridine

Cat. No.: GC65934

Chemical Properties

Cas. No. 1141397-80-9


Formula $C_9H_{14}F_2N_2O_5$ M.Wt 268.21

Solubility DMSO : 50 mg/mL (186.42 mM); ultrasonic and warming and heat to 60°C) Storage 4°C, protect from light

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure



Background

IC₅₀: 0.4 μM (CDA)^[1]

Cedazuridine (E7727) (Compound 7a) is an orally active **cytidine deaminase (CDA)** inhibitor with an **IC₅₀** value of 0.4 μM. Cedazuridine can be used for cancer research ^[1].

Cedazuridine (Compound 7a) exhibits superior acid stability ^[1].

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

Cedazuridine (0-10 μ M; 72 h) does not enhance effects of AZA ([5-Azacytidine](#), HY-10586) in growth inhibition of AML cell lines^[2].

Cedazuridine (3 mg/kg; p.o.; daily for 7 days) in combination with 2.5 mg/kg AZA shows tumor regression in mice MOLM-13 CDX and PDX models^[2].

Animal Model: Female NSGS mice, 6-8 weeks old, human cell line-derived (CDX) and primary patient-derived xenograft (PDX) models^[2]

Dosage: 3 mg/kg

Administration: Oral administration, in combination with 2.5 mg/kg AZA, daily for 7 days

Result: Led to reduction of leukemic expansion in combination with AZA in a cell line-derived xenograft transplantation, and exhibited preliminary safety and efficacy in a primary AML PDX model.

Animal Model: NSGS male mice^[2]

Dosage: 1, 3, 10 and 30 mg/kg

Administration: Oral, in combination with 2.5 mg/kg AZA (Pharmacokinetic Studies)

Result: Dose-dependently increased the AUC of oral AZA and in comparison to dosing of standard i.p. AZA.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA